Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. more
Time Frame | EPRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.33% | 0.31% | -1.26% |
1-Month Return | -11.58% | 0.6% | -4.16% |
3-Month Return | 28.81% | -9.44% | -0.46% |
6-Month Return | 13.43% | -5.15% | 3.58% |
1-Year Return | 3.05% | 0.33% | 22.47% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | 116.81K | 111.53K | 193.27K | 209.91K | [{"date":"2020-12-31","value":55.65,"profit":true},{"date":"2021-12-31","value":53.13,"profit":true},{"date":"2022-12-31","value":92.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | (116.81K) | (111.53K) | (193.27K) | (209.91K) | [{"date":"2020-12-31","value":-11680900,"profit":false},{"date":"2021-12-31","value":-11152900,"profit":false},{"date":"2022-12-31","value":-19327300,"profit":false},{"date":"2023-12-31","value":-20991100,"profit":false}] | |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] | |
Operating Expenses | 2.25M | 18.68M | 23.20M | 37.92M | [{"date":"2020-12-31","value":5.92,"profit":true},{"date":"2021-12-31","value":49.25,"profit":true},{"date":"2022-12-31","value":61.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (2.25M) | (20.87M) | (22.63M) | (36.90M) | [{"date":"2020-12-31","value":-224576600,"profit":false},{"date":"2021-12-31","value":-2087242600,"profit":false},{"date":"2022-12-31","value":-2263460700,"profit":false},{"date":"2023-12-31","value":-3689674300,"profit":false}] | |
Total Non-Operating Income/Expense | (3.24M) | (6.43M) | (615.12K) | (2.60M) | [{"date":"2020-12-31","value":-323971555,"profit":false},{"date":"2021-12-31","value":-642539868,"profit":false},{"date":"2022-12-31","value":-61512300,"profit":false},{"date":"2023-12-31","value":-259516900,"profit":false}] | |
Pre-Tax Income | (4.01M) | (23.37M) | (23.92M) | (39.18M) | [{"date":"2020-12-31","value":-401063800,"profit":false},{"date":"2021-12-31","value":-2336955100,"profit":false},{"date":"2022-12-31","value":-2391721500,"profit":false},{"date":"2023-12-31","value":-3918470800,"profit":false}] | |
Income Taxes | 1.87M | (1.34M) | 930.52K | (89.67K) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-71.93,"profit":false},{"date":"2022-12-31","value":49.81,"profit":true},{"date":"2023-12-31","value":-4.8,"profit":false}] | |
Income After Taxes | (5.88M) | (22.03M) | (24.85M) | (39.10M) | [{"date":"2020-12-31","value":-587883500,"profit":false},{"date":"2021-12-31","value":-2202581700,"profit":false},{"date":"2022-12-31","value":-2484773400,"profit":false},{"date":"2023-12-31","value":-3909504100,"profit":false}] | |
Income From Continuous Operations | (3.15M) | (18.33M) | (18.99M) | (28.97M) | [{"date":"2020-12-31","value":-314520374,"profit":false},{"date":"2021-12-31","value":-1832877210,"profit":false},{"date":"2022-12-31","value":-1899076400,"profit":false},{"date":"2023-12-31","value":-2896600600,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (4.00M) | (22.99M) | (23.26M) | (37.39M) | [{"date":"2020-12-31","value":-399720200,"profit":false},{"date":"2021-12-31","value":-2298960600,"profit":false},{"date":"2022-12-31","value":-2325937300,"profit":false},{"date":"2023-12-31","value":-3739170800,"profit":false}] | |
EPS (Diluted) | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
EPRX | |
---|---|
Cash Ratio | 3.65 |
Current Ratio | 4.17 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
EPRX | |
---|---|
ROA (LTM) | -98.68% |
ROE (LTM) | -314.41% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
EPRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.23 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
EPRX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 6.20 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) share price today is $3.04
Yes, Indians can buy shares of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) on Vested. To buy Eupraxia Pharmaceuticals Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EPRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) via the Vested app. You can start investing in Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) with a minimum investment of $1.
You can invest in shares of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) via Vested in three simple steps:
The 52-week high price of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is $4.08. The 52-week low price of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is $2.2.
The price-to-earnings (P/E) ratio of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is
The price-to-book (P/B) ratio of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is 6.20
The dividend yield of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is 0.00%
The market capitalization of Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is $108.29M
The stock symbol (or ticker) of Eupraxia Pharmaceuticals Inc. Common Stock is EPRX